About PharmaKodex

PharmaKodex Ltd is a specialty pharmaceuticals company developing and commercialising small molecule drugs to treat pain and neurological conditions.

PharmaKodex exploits its proprietary drug delivery and formulation technologies to enhance existing drugs, provide faster acting, more convenient or more effective products, as well as synergistic combinations, which are protected by strong intellectual property.

PharmaKodex’s pipeline includes differentiated clinical stage products that address the pain and neurology markets; capitalising on well documented efficacy and safety profiles to reduce the development risk.

PharmaKodex was spun out from Vectura Group plc and Unilever plc in May 2006 to develop the proprietary formulation and delivery product assets from both companies. PharmaKodex is privately owned and funded by a syndicate of blue chip International investors including Apposite Capital, SROne and Unilever Ventures.

PharmaKodex is based in Cambridge and Chippenham, UK.

Board of Directors

Rod Richards – Chief Executive Officer

Keith Churchman – Chief Financial Officer

John Staniforth – Chief Scientific Officer

Brad Wilson - Chairman

Debbie Harland – Non-Executive Director

Andrew Lane – Non-Executive Director

Allan Marchington – Non-Executive Director

Andrew Richards – Non-Executive Director